Senti Biosciences Inc., a synthetic biology company developing an immuno-oncology drug, has landed a $53 million series A round led by New Enterprise Associates. The money is expected to help advance its cancer asset to the starting line for an investigational new drug filing and accelerate the scaling of what it calls a "genetic circuit programming platform."